Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Year ended March 31, 2026
Nature of Filing / Announcement: Revised Audited Standalone and Consolidated Financial Results
Audit Opinion:
Standalone Results: Unmodified Opinion
Consolidated Results: Qualified Opinion
Auditor’s Comment:
The qualified opinion on the consolidated results is due to the inclusion of unaudited financial statements from three US subsidiaries (Orchid Pharmaceuticals Inc., USA; Bexel Pharmaceuticals Inc., USA; Diakron Pharmaceuticals, Inc. USA). The auditors could not express an opinion on the completeness and true and fair view of these subsidiaries' financials, which had total assets of ₹385.59 lakhs but nil revenue and profit for the period.
Key Financial Highlights [Amounts in lakhs of Indian Rupees]:
Standalone Results:
Revenue from Operations (FY26): ₹1,23,277.84 (FY25: ₹1,39,761.17) [YoY decrease]
Total Income (FY26): ₹1,28,926.53 (FY25: ₹1,43,404.35)
Net Profit (FY26): ₹3,462.00 (FY25: ₹14,189.71) [Significant YoY decrease]
EPS (FY26): ₹5.78 (Basic and Diluted) (FY25: ₹23.69)
Other Equity (as of Mar 31, 2026): ₹1,58,679.07
Cash and Cash Equivalents (as of Mar 31, 2026): ₹130.46
Consolidated Results:
Revenue from Operations (FY26): ₹1,23,277.84 (FY25: ₹1,39,761.17) [YoY decrease]
Total Income (FY26): ₹1,28,926.53 (FY25: ₹1,43,404.35)
Net Profit (attributable to owners) (FY26): ₹995.91 (FY25: ₹13,507.05) [Significant YoY decrease]
EPS (FY26): ₹1.66 (Basic and Diluted) (FY25: ₹22.55)
Other Equity (as of Mar 31, 2026): ₹1,50,442.18
Cash and Cash Equivalents (as of Mar 31, 2026): ₹707.30
Segment-wise Performance:
The company operates in a single segment, "Pharmaceuticals," as per Ind AS 108. No segment-wise breakdown is provided.
Corporate Actions:
No dividend declarations, share splits, bonus issues, or buybacks were announced in this filing.
Other Significant Information:
Merger Impact: The financial results have been revised to reflect the merger with Dhanuka Laboratories Ltd. from the appointed date (April 1, 2024), as required by Ind AS 103.
Exceptional Items: An exceptional item of ₹22.02 lakhs was recorded in Q4 FY26 for incremental estimated liabilities relating to gratuity and leave under the new Labour Codes. This is in addition to a ₹711.27 lakhs provision made in Q3 FY25, bringing the total exceptional charge for FY26 to ₹733.29 lakhs.
Acquisitions: The company successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH, Germany, and Allecra Therapeutics SAS, France, gaining 100% global ownership of the antibiotic Enmetazobactam (EXBLIFEP/Orblicef). It also acquired 100% share capital of Weilchensee 1272. V V GmbH (now Orchid Pharma Europe GmbH), a wholly-owned subsidiary, effective July 30, 2025.
QIP Fund Utilization: The company raised ₹39,454 lakhs (net) through a Qualified Institutional Placement (QIP) in June 2023. As of March 31, 2026, ₹33,256 lakhs had been utilized: ₹19,546 lakhs for debt repayment, ₹7,302 lakhs for investment in a subsidiary (OBPL) for a Jammu facility, ₹36 lakhs for API facility capex in Alathur, and ₹6,372 lakhs for general corporate purposes. ₹6,198 lakhs remained unutilized in fixed deposits.